FDA Cardio-Renal Drugs Advisory Committee

Oct. 13 meeting will discuss broader indication for Squibb's Capoten (captopril) in congestive heart failure; and Merck's Vasotec (enalapril) and Prinivil (lisinopril) as second line treatment in conjunction with digitalis and diuretics. Meeting will be held at Lister Hill auditorium. Capoten is already approved for second-line treatment of congestive heart failure. Prinivil, a second-generation ACE inhibitor, has not been approved for either use. In 1986, Merck exchanged U.S. comarketing rights to lisinopril to Stuart, which will market the product under the brand name Zestril.